Stocks
Actelion LtdALIO
HealthcareBiotechnology
A biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular and pulmonary diseases, with a particular emphasis on pulmonary arterial hypertension. Its lead product, Tracleer, became a standard of care in the field, and the company's pipeline and market performance attracted significant investor attention before its acquisition by Johnson & Johnson in 2017.
Congressional Interest in Actelion Ltd (ALIO)
1 member of Congress has disclosed 1 trade in Actelion Ltd (ALIO), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading ALIO?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-04-02 | KENNY MARCHANT | buy | $1K-$15K |